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Summary Cyclosporin A (CsA) is an effective modulator of multidrug resistance (MDR) in vitro and in
murine tumour systems in vivo. We now report the production of immunity to L1210 leukaemia by the
addition of CsA to VP-16 therapy ofleukaemic BDF/1 mice. VP-16/cyclosporin A tumour immunity induction
arises as a consequence of active therapy independently of immunisation with modified tumour cells. The
addition of CsA to VP-16 prolongs survival of BDF/1 host mice bearing L1210 leukaemia beyond that
produced by equivalent dose VP-16 alone. A subpopulation of 60-day surviving mice after combined
VP-16/CsA are immune to rechallenge with the same leukaemia inoculum to which they were originally
exposed.
Spleen cells from immune mice adoptively transfer anti-L1210 leukaemia immunity to untreated BDF/1
mice in a dose dependent, statistically significant manner. Adoptive transfer experiments additionally suggest
active recruitment of immunologic response in recipient animals: (1) We have been able to perpetuate
leukaemia immunity in four sequential cohorts of naive recipient mice. This propogation ofadoptive immunity
is accomplished by use of spleen cells harvested from each preceeding passively-protected animal cohort; (2)
Cyclophosphamide pretreatment of adoptive transfer recipient mice abrogates the ability of their splenocytes
to perpetuate passive protection in sequential adoptive transfer experiments.
Since chemotherapeutic drugs kill tumour cells by first order
kinetics (Frei, 1972; Skipper, 1965) it has been suggested that
eradication of a neoplastic process, coincident with effective
in vivo chemotherapy, requires a host immune response to
residual viable tumour cells. Indirect support for this concept
derives from the observations that lower, rather than higher
doses of cyclophosphamide produce greater cure rates in
certain rodent tumours, and that, alkylating agent therapy
has been reported to be more effective against experimental
tumours in intact compared to immunosuppressed hosts
(Mathe et al., 1977; Mokyr et al., 1983; MoQre et al., 1973).
We previously reported that cyclosporin A (CsA), the
endecapeptide immunosuppressive antibiotic, was an effective
modulator of multidrug resistance (Slater et al., 1986a,b). We
now describe our use of CsA to enhance the effect of VP-16,
the topoisomerase II inhibitor, on survival of BDF/I mice
with drug sensitive L1210 leukaemia and demonstrate its
paradoxical production of anti-leukaemic immunity in long
surviving host mice.
Methods
Groups of ten or more BDF/1 mice were inoculated intra-
peritoneally (ip) with 100,000 L1210 leukaemia cells, freshly
harvested from leukaemia bearing stock DBA/2 mice (Simon-
sen, Gilroy, CA). Host mice were treated with VP-16 (VePe-
sid, Bristol) 5 mg kg-', ip on days 1 and 3 alone or combined
with CsA (Sandimmune, Sandoz). Two CsA regimens were
employed, 2 and 10mgkg-', the former because it is lower
than the 3-5mgkg-', daily intravenous CsA dose used in
humans (Canafax et al., 1983). Alternate groups ofmice were
treated with a high dose VP-16 regimen of 60 mg kg-', ip on
day 1 after leukaemia inoculation without CsA. Since the
mean survival of BDF/1 mice inoculated with 100,000 L1210
leukaemia cells is in the range of 9-12 days, 60-day surviving
mice, produced by high dose VP-16 alone or combined low
dose VP-16 and CsA, were rechallenged, ip, with 100,000
L1210 leukaemia cells. Animal care was in accord with insti-
tutional guidelines.
For passive transfer experiments control and long-surviv-
ing mice were sacrificed by cervical dislocation. Spleens were
dissected free and cell suspensions prepared by mechanical
disruption into Earle's balanced salt solution. Aliquots of the
spleen cell suspension were counted on a haemocytometer
and admixed in varing ratios with freshly harvested L1210
leukaemia cells for inoculation into untreated BDF/l mice.
In experiments requiring recipient immunosuppression cyclo-
phosphamide, 250 mg kg- , was given ip 24 h prior to
adoptive transfer. Survival differences between control and
experimental groups was analysed by chi square and unless
specified, Mantel-Cox analysis.
In experiments which combined CsA with vincristine
(VCR) or with daunorubicin (DNR), VCR, 1 mg kg- or
DNR, 2.4 mg kg- was given on days 2, 4 or 6 with or
without CsA 10mgkg-'. Cis-platinum (CDDP), 3 mgkg'
was given on day 2 with or without 10 mgkg-' CsA. All
drugs were given intraperitoneally.
Results
Figure la displays survival curves for leukaemia mice either
untreated, treated with low dose VP-16 alone (5 mgkg-'),
high dose VP-16 alone (60 mg kg-') or combined low dose
VP-16 and CsA. In comparison to the 30 to 40% 60-day
survival produced by combined low dose VP-16 and CsA the
high dose VP-16 regimen of 60 mg kg-' without CsA pro-
duced a 55% 60-day survival. Multiple repeated similar
experiments produced over 60-day survival in 32% of 237
VP-16/CsA treated mice, using the 5 mg kg- VP-16 and
10mg kg-' CsA regimen.
Mean survival in days of BDF/I mice with L1210 leukae-
mia treated with VCR, DNR or CDDP alone or with the
addition of CsA were 12.8 ± 1.8 vs 4.9 ± 0.3, 14.7 + 3.6 vs
12.4 ± 1.4 and 14.3 ± 2.1 vs 13.5 ± 1.5 days respectively. Sur-
vival of untreated control mice was 9.2 ± 0.8 days.
Responses of 60-day surviving mice to repeat L1210 leu-
kaemia inoculation are shown in Figure lb. The survival of
mice originally treated with VP-16/CsA is compared to that
of normal non-treated BDF/1 mice and mice previously
treated with high dose VP-16 without CsA. Forty percent
survival can be seen in animals previously treated with com-
bined VP-16/CsA compared to 100% mortality in untreated
control mice and in mice previously treated with the high
dose VP-16 regimen. Chi-square value for survival equals 5.2
P<0.05 for the combined treatment group vs the untreated
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we prepared spleen cell suspensions from normal control and
immune mice, admixed immune or non-immune spleen cells
with L1210 leukaemia cells and challenged new groups offive
or more BDF/l mice with 10,000 L1210 leukaemia cells.
Figure 2a compares the survival curves of BDF/l mice given
L1210 leukaemia with non-immune spleen cells, lymphoid to
tumour cell ratio of 1000:1, to the survival of BDF/l mice
given L1210 leukaemia with immune spleen cells in lymphoid
to tumour ratios of 100:1 and 1000:1. A dose dependent
passive transfer of immunity is apparent with respective P
value of 0.04 between control and the immune lymphoid-
tumour ratio of 100:1 group, and 0.0003 between control and
the immune lymphoid-tumour ratio of 1000:1 group. In a
similar experiment, immune spleen cells harvested on day 137
post initial therapy given in a ratio of 3000:1 in the 10,000
L1210 leukaemia cell inoculation produced prolonged survi-
val in 80% of recipient mice.
Duplicate experiments were performed in which immune
spleen cells, harvested from a different cohort of mice surviv-
ing over 60 days after VP-16 (5mgkg-')/CsA (10mgkg-'),
were admixed in a ratio of 1000:1 with L1210 leukaemia
cells. No enhancement in survival was observed in mice that
received 10,000 leukaemia cells admixed, in this ratio, with
non-immune spleen cells, compared to mice challenged with
L1210 leukaemia alone (mean survival 12.7 ± 1.5 vs 13.8 +
Survival (days)
Figure 1 a, Survival curves of BDF/l mice bearing L1210 leu-
kaemia untreated ( ) treated with VP-16, 5 mg kg-' (- -),
VP-16, 60mgkg' (A A) or combined VP-16, 5mg kg-' and
CsA, 2mg kg-' CsA (.) or VP-16, Smgkg ' and CsA, 10mg
kg-' ( ). b, Survival of BDF/1 mice following challenge
with 1 x 105 L1210 cells (arrows). ( ) untreated control mice;
(A A A) over 60 day survivors of an original 100,000 L1210 cell
inoculum after high dose VP-16 (60 mg kg-' ip on day 1); (- - -)
Over 60 day survivors of an original 100,000 L1210 cell inoculum
after combined VP-16/CsA treatment. This group was additional-
ly rechallenged on day 26 and the animals sacrificed on days 54
and 137 (*) for spleens.
control group and 5.7, P<0.02 vs the high dose VP-16
treatment group. Analysis of data was performed prior to
day 54, at which time animal sacrifice was carried out for
splenocyte harvest. On day 26 surviving animals were
challenged for a third time with 100,000 leukaemia cells. This
challenge had no effect on survival. In a repeat of this
experiment three of ten long term surviving mice after com-
bined treatment using 5 mg kg-' VP-16 and 10 mg kg-' CsA,
survived second and third challenges with 100,000 L1210 cells
on days 42 and 77 after initial therapy. No animals that
survived a second challenge succumbed to a third challenge
of 100,000 L1210 cells. Pooled data from seven independent
experiments confirmed the production of immunity to L1210
leukaemia, as demonstrated by rejection of leukaemia
rechallenge, in 20% of 75 60-day surviving mice after com-
bined VP-16/CsA therapy.
In experiments designed to test the requirement for the
presence of L1210 cells for the initiation of immune protec-
tion, the mean survival of groups of mice pretreated with
CsA alone (0mg kg-'), VP-16 alone (5 mg kg-') and com-
bined VP-16 and CsA, 60 days prior to challenge with L1210
leukaemia was 10.8 ± 3.0, 10.8 ± 1.6, and 11.3 ± 2.0 days
respectively, compared to an untreated mean survival of
10.3 ± 0.5 days.
In order to determine if spleen cells from immune BDF/I
host mice could adoptively transfer anti-leukaemic immunity,
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Figure 2 a, Comparison of survival of BDF/1 mice following
challenge with 1 x 104 L1210 cells given with spleen cells obtained
from non-immune or immune BDF/I mice. ( ) Control
mice given 1000:1 non-immune spleen cells to L1210 leukaemia
cells; (---) mice given 1000:1 immune spleen to L1210 cells;
( -) Mice given 100:1 immune spleen to L1210 cells. Sur-
vival differences by Mantel-Cox analysis are significant between
animals receiving non-immune vs 100:1, and 1000:1 immune
spleen cells, P = 0.04 and P =0.003 respectively. b, Comparison
of survival of BDF/I mice using 1000:1 immune spleen cells to
L1210 leukaemia cells as in a, data pooled from three indepen-
dent experiments, P<0.0001. Arrows indicate rechallenge with
I x 104 L1210 cells.
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0.8 days respectively). Whereas a survival plateau was
observed in five of 11 mice that received the immune spleen
cell - L1210 leukaemia admixture, P<0.0001 vs the non-
immune spleen cell - L1210 leukaemia control group. Figure
2b presents the pooled comparision of survival from three
independent experiments of mice that received the immune
spleen cell L1210 leukaemia admixture (n =26), P<0.0001
vs the non-immune spleen cell admixture (n = 49). Because
these animals withstool leukaemia rechallenges on days 49
and 84 we compared the ability of their splenocytes to pro-
tect a subsequent cohort of normal BDF/1 recipient animals,
when admixed in a ratio of 1000:1 with 10,000 L1210 leu-
kaemia cells, i.e. spleen cells from animals that had pre-
viously received L1210 leukaemia plus immune spleen cells
were used to protect naive recipients. Figure 3 shows perpe-
tuation of the passive protective effect against L1210 leu-
kaemia by these splenocytes vs control spleen cells, to three
subsequent cohorts of recipient animals when splenocytes
harvested from each preceding cohort are admixed with
L1210 leukaemia, P<0.01, 0.0001 and 0.0001 respectively.
In order to determine if the production of leukaemia
immunity in passively protected recipient mice requires the
contribution of an autologous immune response, survival of
cyclophosphamide pretreated animals was compared to sur-
vival ofnon-immunosuppressed control recipients in adoptive
transfer experiments. Figure 4a shows no difference in
survival between these groups. It should be noted, however,
that there is striking difference in survival between a subse-
quent cohort of normal recipient animals inoculated with
L1210 leukaemia admixed with splenocytes obtained from
the non-immunosuppressed vs the previously cyclophospha-
mide immunosuppressed animals when they are used as
splenocyte donors, Figure 4b, P<0.0002.
Discussion
Our experiments show that the addition of CsA to VP-16
prolongs survival ofhost mice bearing L1210 leukaemia com-
pared to equivalent dose VP-16 alone and that immunity to
L1210 leukaemia develops in a significant subset of long
surviving animals. This CsA effect seems uniquely related to
VP-16 since the addition of CsA to vincristine, daunorubicin
or cis-platinum fails to enhance survival of mice with L1210.
Since the in vitro addition of CsA to VP-16 enhances VP-16
cytotoxicity against L1210 leukaemia cells (unpublished
observation) the survival enhancement we observe upon
treatment of leukaemia mice with combined VP-16/CsA
probably reflects favourable pharmacological interaction as
well as immunologic modulation. The development of
immunity to L1210 leukaemia in our experiments is speci-
fically related to the use of CsA since long surviving mice
produced by treatment with higher dose VP-16 without CsA
remain susceptible to leukaemia challenge. Its production
does not represent non-specific immune modulation since
animals treated with VP-16 and/or CsA in the absence of
L1210 leukaemia fail to show increased survival upon subse-
quent leukaemia challenge 60 days later.
Goldin et al. originally reported the ability of long surviv-
ing mice, produced by successful treatment of L1210 leu-
kaemia with amethopterin derivatives, to reject subsequent
L1210 leukaemia challenge (Goldin et al., 1959). It was not
possible to adoptively transfer this immunity (Goldin et al.,
1960). Mihich subsequently succeeded in passive transfer of
L1210 leukaemia immunity by pretreatment of normal mice
4 h prior to L1210 leukaemia challenge with splenocytes or
lymph node cells, obtained from long surviving cytosine
arabinoside-nitrosourea treated host animals (Mihich, 1969).
It is unclear if the explanation for these early observations
relates to immune modulating effects of cytotoxic chemo-
therapy. Subsequent reports suggest this association, as both
chemotherapeutic augmentation of immune effector cells and
inhibition of tumour suppressor cells have been described
(Barker & Mokyr, 1988; Berendt & North, 1980; North,
1982).
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Figure 3 a, Comparison of survival of BDF/1 mice following
challenge with I x 104 L1210 cells given with 1000:1 spleen cells
obtained from non-immune (solid line) or passively protected
(broken line) BDF/l mice, P = 0.01. b, and c. Protection of
sequential groups of BDF/1 recipient mice given spleen cells
harvested from each preceding passively protected cohort admix-
ed 1000:1 with 1 x 104 L1210 cells (broken lines) vs animals given
control spleen cells 1000:1 with 1 x 104 L1210 cells (solid lines),
P<0.0001.
Cyclosporin A, the potent immunosuppressive antibiotic,
cannot only promote organ survival in allotransplantation
but also, paradoxically, break tolerance to self producing
organ specific autoimmune disease in mice (Sakaguchi &
Sakaguchi, 1988). Although CsA fails to alter suppressor cell
alloreactivity, it has recently been shown that CsA selectively
abrogates suppressor L3T4 cells and Lyt-2+ T cells in the
murine thymus. Thymic engraftment from CsA treated
euthymic mice into syngeneic athymic nude mice produces
autoimmune disease in recipient animals (Sakaguchi & Saka-
guchi, 1988).
In 1983 Glazier et al. reported the development of syn-
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Figure 4 a, Comparison of survival of BDF/I mice following
challenge with 1 x 104 L1210 cells given with 1000:1 immune
spleen cells. Solid line represents normnal recipient and broken line
cyclophosphamide immunosuppressed recipient animals. b, Com-
parison of survival of BDF/I mice which received 1 X 104 L1210
cells with 1000:1 spleen cells harvested either from the non-
immunosuppressed (solid line) or immunosuppressed animals
(broken line) depicted in panel a, P = 0.0002.
geneic graft vs host disease (sGVHD) in CsA treated, lethally
irradiated rats after bone marrow reconstitution (Glazier et
al., 1983). Syngeneic graft vs host disease developed after the
withdrawal of chronic CsA therapy following marrow trans-
plantation, and could be adoptively transferred to irradiated
but not to normal syngeneic recipients. It was later shown
that sGVHD is age and thymus dependent and that cyto-
toxic, autoreactive T splenocytes with polyclonal anti-Ia
specificity and activity against a syngeneic Ia positive plasma-
cytoma could be harvested from rats undergoing the sGVHD
reaction (Hess et al., 1985; Geller et al., 1989). Reactivity was
maximal at the onset of clinical sGVHD after withdrawal of
CsA, and declined to baseline as sGVHD symptoms resolved
(Geller et al., 1989). Although our L1210 leukaemia cells
demonstrate Ia antigenicity, as determined flow cytometric-
ally using indirect immunofluorescent staining of Anti I-Ad
(Becton-Dickinson) monoclonal antibody (unpublished
observation), immune animals fail to display signs of
sGVHD.
Our experiments also show that passively protected first
cohort mice are immune to leukaemia rechallenge. Spleno-
cytes harvested from these animals are capable of protecting
a second cohort of naive recipient mice. Splenocytes from the
second cohort protect a third cohort, and third cohort sple-
nocytes, in turn protect a fourth group of naive recipient
animals. These events may relate to proliferation of donor
cells in syngeneic hosts or immunological recruitment and
expansion of recipient responses. Strongly in favour of the
latter possibility is our observation relating to cyclophos-
phamide pretreatment of adoptive transfer recipient mice.
Cyclophosphamide pretreatment of adoptive transfer recipi-
ent mice abrogates the ability of their splenocytes to per-
petuate passive protection in sequential adoptive transfer
experiments. Although cyclophosphamide can inhibit anti-
tumour immunity by ablating suppressor cells (Hess et al.,
1980) our observations are inconsistent with such a possi-
bility since survival ofcyclophosphamide pretreated and non-
pretreated adoptive transfer recipient animals are the same.
The pharmacologic concept that chemotherapeutic agents
produce a constant precent tumour cell kill is well established
(Frei, 1972; Skipper, 1965) and it is widely felt that the cure
of an intact animal after effective chemotherapy relates to the
host response. Our current observations are probably an
example of this phenomenon, since both cytotoxic and
immunologic enhancement are produced by VP-16/CsA inter-
actions.
Experiments are in progress to determine the mechanism
of CsA initiated immunity in L1210 leukaemia and the
splenic cellular population(s) responsible for its adoptive
transfer.
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